Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537719 · ClinicalTrials.gov registry record · Phase 1
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00537719 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 34 participants.
The verdict
NCT00537719, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
Interventions
- DRUG Placebo
- DRUG GSK716155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-12-07 |
| Est. Completion | 2008-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537719
The ClinicalTrials.gov registry entry for NCT00537719 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00537719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537719 about?
NCT00537719 is a clinical study titled "Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.". This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
What is the current status of trial NCT00537719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2007-12-07. Estimated completion is 2008-04-04.
What interventions are being tested in trial NCT00537719?
The interventions under investigation include: Placebo (DRUG), GSK716155 (DRUG).
Who is sponsoring clinical trial NCT00537719?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.